Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyModified FOLFIRINOX Versus CISGEM Chemotherapy for Patients with Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

This open-label, randomized phase II-III study of 191 patients with locally advanced or metastatic BTC compared triplet therapy of oxaliplatin, irinotecan, and infusional fluorouracil (mFOLFIRINOX), with doublet therapy consisting of cisplatin and gemcitabine (CISGEM). Triplet therapy did not outperform doublet therapy in this study.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form